Divergent Effects of Catecholamines on Peritoneal Mass Transport

Hirszel, Przemyslaw; Lasrich, M; Jf, Maher

doi:10.1097/00002480-197902500-00022

Cited by 21 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The resultant alteration of the mesenteric blood flow most likely favors a further decrease of peritoneal solute permeability. In line with this hypothesis, intravenous vasopressor doses of norepinephrine have been shown to reduce peritoneal clearances of creatinine and urea in rabbits (23).…”

Section: Discussionmentioning

confidence: 87%

Enhancement of the Transmesothelial Resistance of the Parietal Sheep Peritoneum by Epinephrine In Vitro: Ussing‐type Chamber Experiments

et al. 2005

View full text Add to dashboard Cite

The peritoneal mesothelium constitutes an ion transport barrier that is taken advantage of in peritoneal dialysis. The aim of this study was to investigate the effects of epinephrine on the electrical transmesothelial resistance (R(TM)) of the isolated parietal sheep peritoneum by means of Ussing-type chamber experiments. Intact parietal (diaphragmatic) peritoneal samples were obtained from adult sheep immediately after sacrifice and transferred within 0.5 h to the laboratory in a cooled Krebs-Ringer bicarbonate solution (4 degrees C, pH 7.5), bubbled with 95% O2-5% CO2. A parietal peritoneal planar sheet was mounted in a Ussing-type chamber. Epinephrine (10(-7) M) was added to the apical and the basolateral side. The R(TM) was measured before and serially after the addition of epinephrine for 30 min. As active ion transport is temperature-dependent, all measurements were performed at 37 degrees C. The results were calculated as means with standard errors (x +/- SE) of six independent experiments. The control R(TM) was 20.05 +/- 0.61 ohm x cm2. The addition of epinephrine to the basolateral side within 1 min induced an increase of R(TM) to 21.8 +/- 0.45 ohm x cm2, which decreased thereafter progressively to reach control values again after 15 min. A similar effect of epinephrine on the apical side was apparent with a rapid rise of R(TM) to 22.5 +/- 0.66 ohm x cm2 and a subsequent decrease (P < 0.05). A clear association between the R(TM) and active ion transport was established from previous studies. The results of our study indicate a rapid action of epinephrine on the parietal peritoneum permeability.

show abstract

Section: Discussionmentioning

confidence: 87%

Enhancement of the Transmesothelial Resistance of the Parietal Sheep Peritoneum by Epinephrine In Vitro: Ussing‐type Chamber Experiments

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The present study shows that the peritoneum‐tumor barrier is partially overcome by the potent vasoconstrictor epinephrine. Alpha‐adrenergic stimulation causes vasoconstriction of the intestinal vascular system and decreases the peritoneal capillary density (Hirzel et al, 1979; Harper et al, 1985). Low doses of epinephrine induce a β 2 ‐receptor‐mediated vasodilatation, whereas higher doses provoke a vasoconstriction.…”

Section: Discussionmentioning

confidence: 99%

Epinephrine enhances penetration and anti-cancer activity of local cisplatin on rat sub-cutaneous and peritoneal tumors

et al. 1999

View full text Add to dashboard Cite

Despite the theoretical advantages of a high local concentration of anti‐cancer drugs, local chemotherapy often fails to produce complete and lasting responses in experimental and human solid tumors. Experiments using Patent Blue dye showed that fluids diffused poorly into tumor mass when injected inside or around s.c. rat tumors in rats. In the same way, Patent Blue dye distributed poorly from the peritoneal cavity into the tumor nodules of rats with peritoneal carcinomatosis. The potent vasoconstrictor, epinephrine (1 mg/kg of body weight) was shown to facilitate the penetration of Patent Blue dye into s.c. and peritoneal rat tumors. Platinum concentration evaluated by micro‐PIXE in s.c. DHD/K12/PROb colon tumors or by atomic absorption spectrometry in DHD/K12/PROb peritoneal tumors was 4‐ to 12‐fold higher when epinephrine was added to local cisplatin. Peri‐tumoral or intra‐tumoral injection of cisplatin (2 mg/kg) alone does not cure s.c. DHD/K12/PROb colon tumors or GV1A1 glioma tumors in BD IX rats. By contrast, a complete and lasting cure of s.c. tumors was achieved regularly and without skin necrosis when epinephrine was added to intra‐tumoral or peri‐tumoral cisplatin. Rats with peritoneal‐tumor nodules 1 to 2 mm in diameter, and insensitive to i.p. cisplatin alone, were cured when the anti‐cancer drug was combined with epinephrine. These experimental results could justify clinical trials using a combination of cisplatin and epinephrine in the treatment of locally growing solid tumors. Int. J. Cancer 81:779–784, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

“…[31] In one study in rabbits, a adrenergic stimulus with norepinephrine decreased urea and creatinine clearance, but the authors did not mention about drainage volume. [32] b-receptor stimulus with intraperitoneal isoproterenol increased the urea and creatinine clearance in rats, [33] but did not affect drainage volume in rabbits [34] and dogs. [35] In our study, the use of carvedilol, an antagonist of a1-and b-adrenergic receptors, had no significant effect on D/P cr ratio at 0, 2, and 4 hours; D/Do glucose ratios at 2 and 4 hours; and UF.…”

Section: Discussionmentioning

confidence: 99%

Comparative Effects of Carvedilol and Lercanidipine on Ultrafiltration and Solute Transport in CAPD Patients

Topal¹,

Erkoç

Sayarlıoğlu

et al. 2009

Renal Failure

View full text Add to dashboard Cite

Background. Peritonitis, the type of buffer used in the dialysate, continue ambulatory peritoneal dialysis (CAPD) of greater than two years duration, increased exposure to dialysate glucose, diabetes mellitus, and the use of beta blockers may contribute to impaired ultrafiltration. Objectives. The aim of the present study is to compare the effects of a calcium-channel blocker and a b-blocker on the peritoneal transport and clearance. Methods. We studied 48 patients with ESRD on chronic peritoneal dialysis, included 27 females and 19 males with mean age 42.6 ± 16.4 years. Two patients were excluded from the study due to peritonitis. Patients were treated either with carvedilol or lercanidipine. In all patients; peritoneal equilibration test (PET), ultrafiltration (UF), Kt/V ratio, creatinine clearance (CrCl), systolic blood pressure, diastolic blood pressure, serum BUN, creatinine, glucose, sodium, potassium, albumin, cholesterol, and triglyceride values were obtained before and after 8 weeks from the start of the drug treatment. Results. Lercanidipine and carvedilol showed a good antihypertensive effect in CAPD patients. Both drugs had a good tolerability profile and showed no effect on plasma lipids. There were no differences in terms of PET, ultrafiltration, Kt/V ratio, CrCl, systolic blood pressure, diastolic blood pressure, serum BUN, creatinine, glucose, sodium, and potassium values between both patient groups. After antihypertensive treatment, neither group showed a difference in the above-mentioned parameters (p > 0.05) except potassium, which was significantly higher in the carvedilol group (p < 0.05). Conclusions. In CAPD patients. short-term usage of carvedilol has no effect on ultrafiltration and solute transport like lercanidipine. Both drugs showed a good antihypertensive effect.

show abstract

Divergent Effects of Catecholamines on Peritoneal Mass Transport

Cited by 21 publications

References 0 publications

Enhancement of the Transmesothelial Resistance of the Parietal Sheep Peritoneum by Epinephrine In Vitro: Ussing‐type Chamber Experiments

Enhancement of the Transmesothelial Resistance of the Parietal Sheep Peritoneum by Epinephrine In Vitro: Ussing‐type Chamber Experiments

Epinephrine enhances penetration and anti-cancer activity of local cisplatin on rat sub-cutaneous and peritoneal tumors

Comparative Effects of Carvedilol and Lercanidipine on Ultrafiltration and Solute Transport in CAPD Patients

Contact Info

Product

Resources

About